Improve your PK profiling with the genO-hSA/hFcRn mouse catalog

Several partners have co-validated the genO-hSA/hFcRn mouse model

‍

Key publications & posters

• CB307:A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors, Archer S, et al. (2024), Clinical Cancer Research.
• Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin, Ma G, et al. (2024), JCI Insight.
• In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders, Vantourout JC, et al. (2021), Bioconjugate Chemistry.
• Generation of a double transgenic humanised neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs, Viuff D, et al. (2015), J Control Release.
• Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1, presented by Avacta at AACR 2021.

‍

What sets the genO-hSA/hFcRn mouse model apart?

• Physiological expression pattern and levels of expression of both hSA and hFcRn
• Serum albumin and FcRn are humanized to optimize drug binding, as murine albumin has higher affinity for hFcRn than human albumin

‍